Journal
GENES & DEVELOPMENT
Volume 35, Issue 13-14, Pages 940-+Publisher
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.348523.121
Keywords
genetics; metabolism; microbiome; PDAC; pancreatic cancer; pancreatic tumor microenvironment; targeted therapy; therapeutic resistance
Categories
Funding
- National Cancer Institute [R01CA245005, R01CA131045, R01CA206105, R37CA237421, R01CA248160, R01CA244931, R01CA245323, R01CA197916, U01CA224193]
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in the United States, with a low survival rate of 10% over 5 years. The disease demonstrates remarkable adaptability and resistance to therapeutic intervention, contributing to its poor prognosis. Recent advances in understanding the biological underpinnings of PDAC have revealed potential vulnerabilities that can be targeted for treatment.
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
